DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

MRI Homepage

What’s new in MR scanners and coils? A review of new innovations arriving on market

Purchasing Insights: The ABCs of buying an MR Facilities must think about their scanning needs of tomorrow when investing today

Siemens gets 7T MR cleared for clinical use in US MAGNETOM Terra offers benefits for neuro and MSK imaging

Contrasting viewpoints on gadolinium Despite evidence of harm, the industry worries about brain retention

MR detects neurological impairments in newborns with CHD before surgery Detects brain impairments even before cardiac surgery

Anthem presses forward with new MR, CT reimbursement guidelines An effort to increase usage of free-standing scan facilities

Merry X-Ray acquires Consensys Imaging Service Expands presence in MR, CT and other imaging modality markets

The future of AI in MR: Supporting clinical decisions Insights from Murat Gungor, vice president of Magnetic Resonance (MR) at Siemens Healthineers North America

MR shielding: out of sight, but hopefully not out of mind Insights from the experts on installation and RF shield maintenance

MR better at detecting Zika fetal brain abnormalities than ultrasound alone Provides greater detail regarding brain structures

MR image of the prostate
Courtesy of Siemens Healthineers

Study finds MR is cost-effective for detecting prostate cancer, guiding biopsies

by Lauren Dubinsky , Senior Reporter
Prostate cancer detection may be on the verge of a paradigm shift.

A new study published in Radiology found that despite the skepticism, MR imaging is cost-effective for detecting the disease and guiding biopsies.

Story Continues Below Advertisement

Because patient safety is the priority

Metrasens is the name top hospitals trust! Click to see how Ferroguard stops threats before Zone 4, or call 630-541-6509



"Many consider MRIs to be cost-prohibitive, especially when evaluating for a common entity such as prostate cancer," Dr. Vikas Gulani, study advisor and professor at Case Western Reserve University School of Medicine, said in a statement. "This was our expectation as well, prior to doing this work, but our study found the opposite."

The current standard for detecting prostate cancer involves retrieving 12 biopsy samples during an invasive transrectal ultrasound procedure. Most tumors are not visible on ultrasound images, so up to 40 percent of clinically significant tumors are missed, according to the research.

MR is more expensive, but it does a better job of detecting these clinically significant cancers. It also can reduce the costly burden of overtreatment because it often doesn't spot low-risk cancer.

A research team from Case Western and University Hospitals Cleveland Medical Center used MR to evaluate the study participants for potentially harmful lesions. They used that data and one of three MR-guided strategies to biopsy the potential foci of cancer or bypassed biopsy if the scan was completely negative.

They found that using MR to detect the lesions and guide biopsies increased standardized quality-adjusted life years for patients, and was cost-effective in about 94 percent of the simulations. The results were consistent across all age groups.

The researchers believe that these findings could help to streamline prostate cancer treatment protocols and reduce overall costs. The costs are rising and expensive; inefficient diagnostic pathways and placing patients in the wrong treatment groups are partially to blame, according to Gulani.

"If we can maximize efficiency in how we identify clinically significant lesions and diagnose patients, we can reduce unnecessary treatments for our patients, and reduce costs to our hospitals," he added.

The Barbara Ann Karmanos Cancer Institute in Detroit announced last month that it's using a combination of 3-D MR and live ultrasound to target prostate biopsies. Their UroNav Fusion Biopsy System fuses the MR and ultrasound images.

"Previously, we used ultrasound alone for biopsies," Dr. Michael Cher, professor at the institute, said in a statement. "Now, with the fusion of the MRI and ultrasound images, we perform targeted biopsies of suspicious areas. We are better at finding cancers, and therefore better at determining the best treatment plan for each patient."

Back to HCB News
  Pages: 1

MRI Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2017 DOTmed.com, Inc.
ALL RIGHTS RESERVED